Remove Drug Delivery Remove Engineer Remove In-Vitro Remove In-Vivo
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. Optimer binders are engineered to overcome these problems. To what do you attribute your success?

article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.